

SINGAPORE MEDICAL GROUP LIMITED
(Company Registration No. 200503187W)
(Incorporated in the Republic of Singapore)

PROPOSED RENOUNCEABLE NON-UNDERWRITTEN RIGHTS ISSUE OF UP TO 25,093,500 NEW ORDINARY SHARES IN THE ISSUED SHARE CAPITAL OF THE COMPANY, AT AN ISSUE PRICE OF S\$0.153 FOR EACH RIGHTS SHARE, ON THE BASIS OF ONE (1) RIGHTS SHARE FOR EVERY TEN (10) EXISTING ORDINARY SHARES IN THE ISSUED SHARE CAPITAL OF THE COMPANY HELD BY ENTITLED SHAREHOLDERS AS AT THE BOOKS CLOSURE DATE, FRACTIONAL ENTITLEMENTS TO BE DISREGARDED (THE “RIGHTS ISSUE”)

(1) RECEIPT OF LISTING AND QUOTATION NOTICE

(2) NOTICE OF BOOKS CLOSURE DATE

The board of directors (the “**Board**”) of Singapore Medical Group (the “**Company**”) refers to the announcement dated 4 November 2014 (the “**4 Nov Announcement**”) in relation to, *inter alia*, the Rights Issue which the Company is intending to undertake.

Capitalised terms not defined herein shall bear the same meanings ascribed to them in the 4 Nov Announcement. Any references to a time of day herein shall be references to Singapore time.

1. LISTING AND QUOTATION NOTICE

The Board wishes to announce that the Company has received the listing and quotation notice from the SGX-ST on 25 November 2014 (the “**L&Q Notice**”) for the listing of and quotation for up to 25,093,500 Rights Shares on the Catalist Board pursuant to the Rights Issue, subject to the Company’s compliance with the SGX-ST’s listing requirements and submission of Part II of Appendix 8B of the Listing Manual.

The issuance of the L&Q Notice is not to be taken as an indication of the merits of the Rights Issue, the Rights Shares, the Company, its subsidiaries and their securities.

The offer information statement (the “**OIS**”), together with all other accompanying documents (if applicable), will be lodged with the SGX-ST, acting as agent on behalf of the Authority, at a later date. An appropriate announcement will be made upon lodgement of the OIS.

2. NOTICE OF BOOKS CLOSURE DATE FOR THE RIGHTS ISSUE

NOTICE IS HEREBY GIVEN that the Register of Members and Share Transfer Books of the Company will be closed at 5.00 p.m. on 9 December 2014 (the “**Books Closure Date**”) for the purposes of determining the provisional allotments of Rights Shares to Entitled Shareholders (being Entitled Depositors and Entitled Scripholders) under the Rights Issue.

3. ELIGIBILITY OF SHAREHOLDERS TO PARTICIPATE IN THE RIGHTS ISSUE

Entitled Depositors

Depositors will be provisionally allotted Rights Shares on the basis of the number of Shares standing to the credit of their securities accounts with CDP as at 5.00 p.m. on the Books Closure Date.

To be “**Entitled Depositors**”, Depositors must have registered addresses in Singapore with CDP as at the Books Closure Date or if they have registered addresses outside Singapore, must provide CDP, at 11 North Buona Vista Drive #06-07 The Metropolis Tower 2 Singapore 138589, with addresses in Singapore no later than 5.00 p.m. on the date being three (3) market days prior to the Books Closure Date, in order to receive their provisional allotments of Rights Shares.

Entitled Scripholders

Scripholders will have to submit duly completed and stamped transfers (in respect of Shares not registered in the name of CDP), together with all relevant documents of title, so as to be received no later than 5.00 p.m. on the Books Closure Date by the Share Registrar, in order to be registered to determine the transferee's provisional allotments of Rights Shares.

To be “**Entitled Scripholders**”, Scripholders must have registered addresses in Singapore with the Company as at the Books Closure Date or if they have registered addresses outside Singapore, must provide the Share Registrar at 80 Robinson Road #02-00 Singapore 068898 with addresses in Singapore no later than 5.00 p.m. on the date being three (3) market days prior to the Books Closure Date, in order to receive their provisional allotments of Rights Shares.

Entitled Shareholders

Entitled Shareholders are at liberty to accept (in full or in part), decline, renounce or in the case of the Entitled Depositors, trade on the Catalist Board during the “nil-paid” rights trading period prescribed by the SGX-ST, their provisional allotments of the Rights Shares and are eligible to apply for additional Rights Shares in excess of their provisional allotments under the Rights Issue.

Foreign Shareholders

For practical reasons and in order to avoid any violation of the securities legislation applicable in countries other than Singapore, the Rights Shares will **NOT** be offered to Foreign Shareholders. As such, no provisional allotments of Rights Shares will be made to, and no purported acceptance and application thereof by Foreign Shareholders will be valid.

If it is practicable to do so, arrangements may, at the discretion of the Company, be made for the provisional allotments of Rights Shares which would otherwise have been provisionally allotted to Foreign Shareholders, to be sold “nil-paid” on the Catalist Board as soon as practicable after dealings in the provisional allotments of Rights Shares commence. The net proceeds from all such sales after deducting all expenses therefrom, will be dealt with in accordance with the terms set out in the OIS.

If such provisional allotments of Rights Shares cannot be or are not sold on the Catalist Board as aforesaid for any reason by such time as the SGX-ST shall have declared to be the last day for trading in the provisional allotments of Rights Shares, the Rights Shares represented by such provisional allotments will be allotted and issued to satisfy excess applications for Rights Shares or disposed of or dealt with in such manner as the Directors may, in their absolute discretion, deem fit and no Foreign Shareholder shall have any claim whatsoever against the Company, Provenance Capital Pte. Ltd., the manager of the Rights Issue, the Sponsor, CDP, the Share Registrar and/or their respective officers in connection therewith.

4. RESPONSIBILITY STATEMENT

The Directors collectively and individually accept full responsibility for the accuracy of the information given in this Announcement and confirm after making all reasonable enquiries, that to the best of their knowledge and belief, this Announcement constitutes full and true disclosure of all material facts about the Rights Issue, the Company and its subsidiaries, and the Directors are not aware of any facts the omission of which would make any statement in this Announcement misleading. Where information in this Announcement has been extracted from published or otherwise publicly available sources or obtained from a named source, the sole responsibility of the Directors has been to ensure that such information has been accurately and correctly extracted from those sources and/or reproduced in this Announcement in its proper form and context.

By Order of the Board

Dr Beng Teck Liang

Executive Director and Chief Executive Officer

25 November 2014

This document has been prepared by the Company and its contents have been reviewed by the Company's sponsor CIMB Bank Berhad, Singapore Branch (the "Sponsor"), for compliance with the relevant rules of the SGX-ST, this being the SGX-ST Listing Manual Section B: Rules of Catalist. The Sponsor has not independently verified the contents of this document.

This document has not been examined or approved by the SGX-ST. The Sponsor and the SGX-ST assume no responsibility for the contents of this document, including the correctness of any of the statements or opinions made or reports contained in this document.

The contact person for the Sponsor is Mr. Eric Wong, Director, Corporate Finance. The contact particulars are 50 Raffles Place #09-01 Singapore Land Tower Singapore 048623, Telephone: +65 6337 5115.